TCT-466 Long-term outcomes following mini-crush versus culotte stenting for unprotected left main coronary artery disease: a substudy from the Milan and New-Tokyo (MITO) registry  by Kawamoto, Hiroyoshi et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5 B191individualized preventive approach and develop a successful quality
control/improvement solution.
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BACKGROUND Both mini-crush and culotte stenting are considered
efﬁcacious options when percutaneous coronary intervention (PCI)
with a planned 2-stent strategy is necessary for unprotected left main
coronary artery (LMCA) disease. However, there are limited data
available regarding to the long-term clinical outcomes of each strategy.
METHODS A retrospective analysis was conducted from the Milan and
New-Tokyo (MITO) registry and included all patients that underwent
PCI to the unprotected LMCA with drug-eluting stents. Between July
2002 and November 2013, 225 patients were identiﬁed (135 patients
treated with the mini-crush technique, and 90 patients with culotte
stenting). The median follow-up period was 1263 (IQR 820–1847) days.
RESULTS The mini-crush group had worse baseline characteristics when
compared to the culotte group. SYNTAX score were higher in the mini-
crush group than in the culotte (SYNTAX score; 30.4  10.5 vs. 27.5  9.4,
p ¼ 0.04). Stents implanted to the side-branch (SB) were signiﬁcantly
smaller and shorter in themini-crush group compared to the culotte group
(SB stent diameter: 2.99 0.38 vs. 3.24 0.34mm, p< 0.001, and SB stent
length: 19.8  6.4 vs. 22.3  5.7 mm, p ¼ 0.004). Intravascular ultrasound
was utilized in 67% of all cases, and ﬁnal kissing balloon inﬂation was
performed in more than 97% in both groups. There were no signiﬁcant
differences inmajor adverse cardiac events (MACE) at 5-years (mini-crush
36.0% vs. culotte 41.4%, p ¼ 0.57). Main-branch (MB)-TLR tended to be
higher in the culotte group (mini-crush 4.0% vs. culotte 9.9% at 5-years,
p ¼ 0.10) although there were no signiﬁcant differences regarding to SB-
TLR. Notably, myocardial infarction (MI) and deﬁnite stent thrombosis
(ST) were signiﬁcantly more frequent in the culotte group (MI; mini-crush
0%vs. culotte 11.3%, log-rankp¼0.003, anddeﬁniteST;mini-crush0%vs.
culotte 6.3%, p ¼ 0.02, respectively). Multivariate Cox regression analysis
revealed that full stent coverage of the LMCA (HR 0.54; 95% CI: 0.32–0.92,
p ¼ 0.02) and SYNTAX score (HR 1.02; 95% CI: 1.00–1.05, p ¼ 0.05) were
independent predictors for MACE.
CONCLUSIONS The incidence of MACE and overall TLR were com-
parable between groups. However, the rates of MI and deﬁnite ST
were signiﬁcantly higher in the culotte group. Full stent coverage of
the LMCA may reduce the incidence of MACE when a two-stent
strategy is used for the treatment of unprotected LMCA disease.
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BACKGROUND There is still uncertainty about the durability of the
results of drug-eluting stents (DES) in real-world complex patients
(pts). We sought to provide the longest clinical follow-up data on
outcomes of unselected patients treated solely with DES.
METHODS The DESIRE registry is a prospective, single-center registry
encompassing all consecutive patients treated solely with DES since
May 2002. The primary goal is the very long-term occurrence of MACE
and stent thrombosis (ST). Patients were clinically followed at 1, 6 and
12 months and then annually. A multivariate model was built to
determine independent predictors of MACE and ST.RESULTS A total of 5,614 pts (8,825 lesions / 9,980 DES) were
included. The mean age was 64  11 years. DM was detected in 31.5%
and 41.8% presented with acute coronary syndrome (STEMI repre-
sented 16.8% of the cohort). Follow-up was obtained in 98.4% of the
patients (median 5.9 years). Currently, 78.9% of the population is free
of any MACE. Ischemia-driven TVR was performed in 7.3% of the
patients. Q-wave MI rate was only 1.7% while cumulative incidence of
deﬁnite/probable ST was 4.1%. Independent predictors of MACE were
initial presentation as ACS (HR 1,4; 95% CI, 1.1 to 1.7, p¼ 0.001), lesion
length >20mm (HR 1.4; 95% CI, 1.2 to 1.6, p<0.001), residual stenosis
(HR 1.02; 95% CI, 1.01 to 1.03, p<0.001), DM (HR 1.6; 95% CI, 1.1 to 2.2,
p¼ 0.006) and severe coronary calciﬁcation (HR 1.4; 95% CI, 1.1 to 1.8,
p¼ 0.004) while use of 2nd generation DES was protective (HR 0.7;
95% CI, 0,5 to 0.9, p¼ 0.007). Independent predictors of ST were PCI
for STEMI (HR 2.6; 95% CI, 1.6 to 4.3, p<0.001) and treatment of small
vessels (HR 2.0; 95% CI, 1.3 to 3.3, p¼0.002).
CONCLUSIONS In our single center experience, the use of DES was
associated with very long-term safety and effectiveness with accept-
able low rates of adverse clinical events, including ST. Treatment of
patients with ACS, in particular STEMI, increase the risk of adverse
events while use of 2nd generation DES might be protective.
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BACKGROUND Despite the data from controlled trials pointing to
improved clinical results with 2nd generation DES as compared to the
1st generation, there is still a paucity of information on their long-
term performance in the “real-world” clinical practice.
METHODS The DESIRE registry is a prospective, single-center registry
with all consecutive patients (pts) treated with DES since May 2002.
To compare the outcomes of pts treated with 1st and 2nd generation
DES, a propensity score model was built to minimize the difference
between the cohorts. The primary endpoint was the comparison of
MACE and stent thrombosis (ST) up to 2 years of follow-up.
RESULTS A total of 5,614 pts were enrolled in the DESIRE. After
propensity score adjustment, the outcomes of 1,135 pairs of pts treated
with 1st and 2nd generation DES were compared. The cohorts were
comparable in terms of clinical proﬁle, with relatively high incidence
of diabetics (33%) and STEMI pts (17%). Conversely, 2nd generation
pts had more LM disease (1.1% vs. 2.3%, p¼0.005), ostial lesions (3.8%
vs. 6.5%, p<0.001) and bifurcations (7.2% vs. 10.3%, p<0.001). In
terms of clinical performance, there was no signiﬁcant difference in
MACE (Figure, panel A) and TLR between the groups, although 2nd
generation DES signiﬁcantly reduced MI (Figure, panel B), and tended
to reduce ST (Figure, panel C).
